Vladimir Putin

Sykes, Sir Richard

View Photos
Listen to Podcast
Watch Live Webcast

The speeches are free of charge but please note that the Empire Club of Canada retains copyright. Neither the speeches themselves nor any part of their content may be used for any purpose other than personal interest or research without the explicit permission of the Empire Club of Canada.

The quest for new medicines and the contribution that research-based pharmaceutical companies like Glaxo Wellcome can make to it. Advances in a number of fields of science and technology over the last two decades; their impact on the way in which human diseases are diagnosed and treated. Significant changes in the way that health care is delivered to our communities. Impact on those changes on health care providers and also upon those industries such as the pharmaceutical and diagnositc industries which supply them. The international nature of the brand-name pharmaceutical industry. A fragmented market with many players. The process of merger and acquisition over the last few years which will continue. The importance of research and development in this industry. The industry's ability to respond to a changing environment, moving away from chemistry as the driving discipline, to the biological, then biotechnical, molecular and cellular sciences. The need to adapt to major changes in the marketplace worldwide, leading to changes in the demand for the industry's products. The expectation of a high standard of health-care provision in societies like Canada. The pressure arising from demographic change, again attributable to improved health care. The rate of increase in costs of delivery of health care and what that has meant to health-care providers: seeking ways to reduce their costs. Patented pharmaceuticals as a target for cost-reductions. The resultant pressure on the industry to seek new approaches. Two views of the way forward emerging in the industry: investment in science and technology to create significant new medicines or investment in the means of provision of existing medicines to ensure continued revenue from old medicines. Glaxo Wellcome's support of the first view, and why. Four things that the pharmaceutical industry must do to remain successful. Glaxo Wellcome's commitment to fighting disease, and to what that commitment extends. Some dollar figures and details of projects. The unprecedented opportunities now available, through harnessing science and technology, to understand disease processes and identify targets for therapeutic intervention which may produce cures. The explosion of biological knowledge and its consequent results. A discussion of some of the developments that are emerging from the human genome project. How developments in information technology can facilitate the delivery of cost-effective health care through disease management, with illustrative example. The need to develop partnerships involving governments, the health-care professions, the academic scientific community and the pharmaceutical and other health-care industries. A description of the process of development, beginning with establishing a patent. The need for policy support in Canada for Glaxo Wellcome's initiatives to continue here. The issue of the 20-year patent protection available in just about every other developed country in the world. An examination of Canada's pertinent regulations, and the need for an efficient and effective approval process. Glaxo Wellcome's role to play in helping keep the costs of health care in check, and examples of how they are doing so. Details of the Glaxo Wellcome/Sunnybrook Drug Safety Clinic.